What is AYTU BIOPHARMA, INC (AYTU)'s fair-value range?

EvidInvest reads AYTU BIOPHARMA, INC (AYTU)'s market price back into the assumptions behind it — the implied P/E, growth rate and cash yield — using its latest filed financials, then lets you set your own. See the full DCF, Graham number, EPV and multiple-based methods at https://evidinvest.com/valuation/AYTU.

How is AYTU BIOPHARMA, INC (AYTU)'s fair value calculated?

AYTU BIOPHARMA, INC (AYTU)'s fair value is computed with several independent methods — a discounted cash flow (DCF) model, the Graham number, earnings power value (EPV), and valuation multiples such as PE and EV/EBITDA — using data from SEC filings. P/B is optional for non-financial companies and included in the preset range for financial sectors.

Which filing are AYTU BIOPHARMA, INC (AYTU)'s valuation inputs based on?

Inputs come from the FY2026 10-K filed 2026-09-22 (accession 0001437749-26-030908). Source: https://www.sec.gov/Archives/edgar/data/1385818/000143774926030908/

Fair value · AYTU BIOPHARMA, INC (AYTU) · updated 2026-10-30 · from 10-K FY2026

AYTU BIOPHARMA trades at $1.93. That price implies a 34.2% free-cash-flow yield.

Name: AYTU BIOPHARMA, INC (AYTU) valuation inputs and fair-value methods
Creator: EvidInvest
License: https://evidinvest.com/subscription-terms

Cboe · delayed 15 min · as of 16:25 ET

Are those assumptions reasonable? Use AYTU’s filed growth history and the AI chat to decide, then set your own inputs below — the range you build is yours.

What the price implies

FCF yield: 34.2%

Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings. This price: Cboe · delayed 15 min · as of 16:25 ET.

Set your own assumptions ↓See how each method got its number Check another stock

Inputs come from the FY2026 10-K filed 2026-09-22 (accession 0001437749-26-030908); set your own on the sliders below. Research, not investment advice.

The filing behind these numbers

AYTU BIOPHARMA, INC

Revenue: $57.6M
Diluted EPS: $-1.16
Free cash flow: $3.3M; operating cash flow − capital expenditure
Diluted shares: 12.3M; weighted average

10-K FY2026 · fiscal year ended 2026-06-30 · filed 2026-09-22 · accession 0001437749-26-030908

Trailing-twelve-month EPS also uses the quarterly 10-Qs through Q4 FY2026 (filed 2026-09-22).

Open this filing on sec.gov

Valuation tool: build your own AYTU range

Fair Value Summary

Daily Price — AYTU

$1.98 -9.2% (1Y)

Your range1 of 7 methods

At least two methods need a usable value to draw a range with these inputs.

Range with preset inputs

$6.44 – $6.44

Price $1.93

Bear $6.44Base $6.44Bull $6.44

The two ranges are identical because every input sits on a preset.

We don’t tell you what AYTU is worth. Every tab OPENS on what today’s price implies for that method’s key assumption; you decide whether that assumption is reasonable — the growth matrix has AYTU’s filed history and the AI chat will reason it through with you — and the range you build is yours. Our presets are filed history and reference settings, never a recommendation.

Discounted cash flow

N/A

Starting free cash flow is not positive; the model has nothing to grow.

Your stage-1 FCF growth (5.0%) is above the -32.6% the price implies.

Preset inputs — revenue-driven DCF from the latest filing

Two-stage FCF model at the same filed inputs: $5.90 — move any slider below and that model takes over.

• Starting free cash flow is not positive; the model has nothing to grow.

Implied by today’s price

At $1.93 the market implies a stage-1 FCF growth of -32.6%. (two-stage FCF model solved for stage-1 growth at 8.53% WACC)

The price implies stage-1 FCF growth of -32.6%, outside the range this slider covers. Showing preset inputs.

Implied discount rate (holding growth): 38.6% · the WACC that makes the same model print the price

That is the assumption the market is making — not ours, and not a recommendation. Decide whether it is reasonable: the growth matrix shows what AYTU has actually filed, and the AI chat will reason it through with you.

Your inputs

Free cash flow grows at your stage-1 rate, then your stage-2 rate, then a terminal rate; everything is discounted at your WACC.

Stage-1 growth5.0%

Yearly free-cash-flow growth for the first stage. Starts below zero so a shrinking-cash-flow case — and the rate today’s price implies — can be set.

-20.0%60.0%

Stage-1 years5 yrs

How long stage-1 growth lasts.

1 yrs10 yrs

Stage-2 growth2.5%

Slower growth after stage 1, before the terminal phase.

-20.0%30.0%

Stage-2 years5 yrs

0 yrs10 yrs

Terminal growth2.5%

Growth forever after the two stages. Above ~3% is rarely justified.

0.0%5.0%

Discount rate (WACC)8.53%

The return you require. Default is the WACC EvidInvest computed for this company. Higher discount rate, lower value.

3.00%15.00%

Net debt ($M)Debt minus cash, from the balance sheet. Subtracted from enterprise value.

Starting FCF ($M)Latest free cash flow from the filing (operating cash flow minus capex).

Shares (M)Diluted shares, from the filing.

Year by year (two-stage model, $M)

PV explicit $24M · PV terminal $32M · EV $57M · equity $71M

Year	Stage	FCF	Present value
1	Stage 1	$3M	$3M
2	Stage 1	$3M	$3M
3	Stage 1	$3M	$3M
4	Stage 1	$4M	$3M
5	Stage 1	$4M	$3M
6	Stage 2	$4M	$2M
7	Stage 2	$4M	$2M
8	Stage 2	$4M	$2M
9	Stage 2	$4M	$2M
10	Stage 2	$4M	$2M

Inputs from the filing

Free cash flow: $3.3M; sum of the last four quarters
EBIT: $-8.3M; latest annual
Shares: 12.3M
Total debt: $12.0M
Cash: $26.3M
Net debt: $-14.3M; debt − cash

10-K FY2026 · period ended 2026-06-30 · filed 2026-09-22 · accession 0001437749-26-030908 · sec.gov

Prefer a blank slate with reverse DCF? Open the standalone DCF / reverse DCF for AYTU

Loading history...

Download the full AYTU valuation report (PDF) — free

DCF fair value, Graham number, EPV, key multiples and growth rates in one clean PDF.

AYTU BIOPHARMA trades at $1.93. That price implies a 34.2% free-cash-flow yield.

The filing behind these numbers

Valuation tool: build your own AYTU range

Daily Price — AYTU

Your range1 of 7 methods

Range with preset inputs

Your inputs

Year by year (two-stage model, $M)

More on AYTU

Compare with peers

Explore

Valuation tool: build your own AYTU range

Daily Price — AYTU

Your range1 of 7 methods

Range with preset inputs

Your inputs

Year by year (two-stage model, $M)

More on AYTU

Compare with peers

Explore